Status:
TERMINATED
Rapid Versus Conventional Titration of Quetiapine in Schizophrenia/Schizoaffective Disorder
Lead Sponsor:
AstraZeneca
Conditions:
Schizophrenia
Schizoaffective Disorders
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to determine whether increasing the amount (dose) of quetiapine IR (immediate release formulation) more rapidly than conventional dose increases, improves the control of s...
Eligibility Criteria
Inclusion
- Men and women, aged 18 to 65 years, who require treatment for an acute episode of schizophrenia/schizoaffective disorder as judged by their doctor
Exclusion
- Significant and unstable conditions of hear, circulation, blood, liver, kidney; malignancies (cancer); diabetes (mellitus); history of fits or fainting. Resistance to antipsychotic medication. Current alcohol/drug abuse. Pregnant/breast feeding women.
Key Trial Info
Start Date :
July 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2007
Estimated Enrollment :
234 Patients enrolled
Trial Details
Trial ID
NCT00457899
Start Date
July 1 2007
End Date
September 1 2007
Last Update
November 27 2007
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Brentwood, Essex, United Kingdom
2
Research Site
Harrow, Middlesex, United Kingdom
3
Research Site
Surbiton, Surrey, United Kingdom
4
Research Site
Birmingham, United Kingdom